Log in to your Inderes Free account to see all free content on this page.
Create account

Bioretec

0.01 EUR

+7.69 %

1,755 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

+7.69 %
-57.58 %
-63.47 %
-74.61 %
-82.81 %
-92.35 %
-92.71 %
-
-94.59 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
18.79M EUR
Turnover
34.51K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
28.04.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 29.04.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.5.
2026

Business review Q1'26

13.8.
2026

Interim report Q2'26

12.11.
2026

Business review Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Inderes Bioretec Oy: Arvopaperimarkkinalain 9 luvun 10 pykälän mukainen ilmoitus... Bioretec Oy Yhtiötiedote 29.4.2026 klo 16:40 Bioretec Oy: Arvopaperimarkkinalain 9 luvun 10 pykälän mukainen ilmoitus omistusosuuden muutoksesta (Sp-Rahastoyhtiö)Bioretec Oy ("Bioretec" tai ... “Bioretec...
4/29/2026, 2:19 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
5
Here are Antti’s pre-match comments as Bioretec reports its Q1 results on Friday. We expect the company’s revenue to decline from the comparison period, which was supported by a one-off order, and the result to remain clearly loss-making. In the report, our attention will be particularly...
yesterday
by Sijoittaja-alokas
3
The share price has shown a fairly positive trend now that the rights issue was successfully completed and the pulse has stabilized. We are already up nearly +40% = 1.36c for those who subscribed with zero-cost subscription rights about a month ago. There are even bots buying in ...
3 hours ago
by Expaco_b
2
According to the release, this was a subscription. The rights issue was ongoing until April 21st. The company approved the subscriptions on April 24th. Management has the same rights as everyone else to subscribe at a certain price. The rules of the closed period do not apply here...
5/6/2026, 1:31 PM
by Vino Pino
2
It can be found on the second page of the exemption document Surely it will be at the upper end of that range, as the amount raised is also close to the maximum. EDIT: and it was apparently mentioned in that Finnish prospectus as well.
4/29/2026, 2:02 PM
by Antti Siltanen
1
Kustaa Poutiainen has carried out a Tecnotree-style takeover. The major shareholder is unlikely to want to burn any more money.
4/29/2026, 6:03 AM
by NOKNOK
1
In Bioretec’s case, the question is whether the share issue will lead to a new rise or if the continuation of wasteful spending has simply been enabled for another 5 quarters. The essential question is why the situation would be any different now compared to previous offerings, where...
4/29/2026, 5:59 AM
by Jopinaattori
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.